STEM-T technology to empower adoptive T cell therapy in solid tumor setting

Calendar Icon - Evently Webflow Template
13 Oct
Clock Icon - Evently Webflow Template

About the Session

  1. One step small molecule approach targeting molecule PA to preserve T cell stemness and delay T cell exhaustion.
  2. Ex vivo reprogramming overcoming the problem of CAR T cell differentiation and loss of stemness during manufacturing process.
  3. Enable CAR T cells to increase their antigen-mediated cytotoxicity while limiting their exhaustion level to increase anti-tumor capacity, efficacy, and persistency in solid tumor models
  4. Applicable to a variety of adoptive T cell therapy including CAR T, TIL and γδT cell therapy with immediate therapeutic effects and long-term protection.
Are you ready?

Get Early Access to
BioCon Asia-ACGT Conference!